Severe acute respiratory syndrome (SARS) is a recently emerged human disease associated with
pneumonia.
Inapparent infection with SARS coronavirus (CoV) is not well characterized. To develop a safe, simple, and reliable screening method for SARS diagnosis and epidemiological study, two recombinant SARS-CoV
nucleocapsid proteins (N'
protein and (N)Delta(121)
protein) were expressed in Escherichia coli, purified by affinity chromatography, and used as
antigens for indirect,
immunoglobulin G enzyme-linked
immunosorbent assays (ELISA). Serum samples collected from healthy volunteers and SARS patients in Vietnam were used to evaluate the newly developed methods. The N'
protein-based ELISA showed a highly nonspecific reaction. The (N)Delta(121)
protein-based ELISA, with a nonspecific reaction drastically reduced compared to that of the nearly-whole-length N'
protein-based ELISA, resulted in higher rates of positive reactions, higher titers, and earlier detection than the SARS-CoV-infected cell lysate-based ELISA. These results indicate that our newly developed SARS-CoV (N)Delta(121)
protein-based ELISA is not only safe but also a more specific and more sensitive method to diagnose SARS-CoV
infection and hence a useful tool for large-scale epidemiological studies. To identify inapparent SARS-CoV
infections, serum samples collected from health care workers (HCWs) in Vietnam were screened by the (N)Delta(121)
protein-based ELISA, and positive samples were confirmed by a virus neutralization test. Four out of 149 HCWs were identified to have inapparent SARS-CoV
infection in Vietnam, indicating that subclinical SARS-CoV
infection in Vietnam is rare but does exist.